Literature DB >> 10088930

Bone mineral content and body composition in children and young adults with cystic fibrosis.

R C Henderson1, C D Madsen.   

Abstract

With dual energy X-ray absorptiometry (DEXA), it is possible to quantitate important aspects of growth in children with cystic fibrosis (CF), supplementing the usual measures of height and weight. Of particular concern during growth is the accumulation of bone mineral, since osteoporosis and fractures are well-recognized problems in end-stage disease. Various measures of growth and body composition were examined in 40 children and young adults (ages 5.7-20.3 years, mean 11.9 years) and compared to age-, gender-, and race-matched normal controls. The mean (+/- SE) weight Z-score of the 40 CF patients was -0.70 +/- 0.11, and the mean height Z-score was -0.66 +/- 0.15. Relative to their matched normal controls, the CF patients had a deficit in total body bone mineral averaging 19.1% +/- 3.0%. The deficits in total body bone mineral correlated with pulmonary and nutritional measures of disease severity. Serum vitamin D levels, calcium intake, age, gender, use of steroids, and CF genotype were not found to be significant factors. In this group of children and young adults with CF, height and weight measures of growth were not dramatically reduced (mean Z-scores = -0.7), yet large deficits in total body bone mineral averaging nearly 20% were identified.

Entities:  

Mesh:

Year:  1999        PMID: 10088930     DOI: 10.1002/(sici)1099-0496(199902)27:2<80::aid-ppul3>3.0.co;2-j

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  10 in total

1.  Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis.

Authors:  H M Buntain; P J Schluter; S C Bell; R M Greer; J C H Wong; J Batch; P Lewindon; C E Wainwright
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

2.  Well-nourished cystic fibrosis patients have normal mineral density, but reduced cortical thickness at the forearm.

Authors:  O Louis; P Clerinx; I Gies; E De Wachter; J De Schepper
Journal:  Osteoporos Int       Date:  2008-06-07       Impact factor: 4.507

3.  Calcium acquisition rates do not support age-appropriate gains in total body bone mineral content in prepuberty and late puberty in girls with cystic fibrosis.

Authors:  K J Schulze; C Cutchins; B J Rosenstein; E L Germain-Lee; K O O'Brien
Journal:  Osteoporos Int       Date:  2006-02-28       Impact factor: 4.507

4.  Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors.

Authors:  S P Conway; A M Morton; B Oldroyd; J G Truscott; H White; A H Smith; I Haigh
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

5.  Bone mineral and body composition alterations in paediatric cystic fibrosis patients.

Authors:  Philippe Reix; Gabriel Bellon; Pierre Braillon
Journal:  Pediatr Radiol       Date:  2009-12-03

Review 6.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

7.  Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study.

Authors:  S P Conway; B Oldroyd; A Morton; J G Truscott; D G Peckham
Journal:  Thorax       Date:  2004-08       Impact factor: 9.139

8.  A roadmap to the brittle bones of cystic fibrosis.

Authors:  Ashwini P Gore; Soon Ho Kwon; Antine E Stenbit
Journal:  J Osteoporos       Date:  2010-12-16

9.  Measures of body habitus are associated with lung function in adults with cystic fibrosis: a population-based study.

Authors:  Doug L Forrester; Alan J Knox; Alan R Smyth; Andrew W Fogarty
Journal:  J Cyst Fibros       Date:  2012-09-05       Impact factor: 5.482

10.  Treatment of cystic fibrosis related bone disease.

Authors:  Jagdeesh Ullal; Katherine Kutney; Kristen M Williams; David R Weber
Journal:  J Clin Transl Endocrinol       Date:  2021-12-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.